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Chapter 4
Plasma Cadmium is Associated with Increased Risk
 of Long-Term Kidney Graft Failure
Camilo G. Sotomayor, Dion Groothof, Joppe J. Vodegel, Michele F. Eisenga, 
Tim J. Knobbe, Jan IJmker, Rosa G.M. Lammerts, Martin H. de Borst, Stefan 
P. Berger, Ilja M. Nolte, Ramón Rodrigo, Riemer H.J.A. Slart, 
Gerjan J. Navis, Daan J. Touw, Stephan J.L. Bakker




The kidney is the most sensitive organ to cadmium-induced toxicity, 
particularly in conditions of long-term oxidative stress. We hypothesized 
that, in kidney transplant recipients (KTR), the nephrotoxic exposure 
to cadmium represents an overlooked hazard for preserved graft 
functioning. We performed a prospective cohort study of 672 outpatient 
KTR with a functioning graft ≥1-year. Med ian plasma cadmium was 
58 (IQR, 43‒75) ng/L. During 4.9 (IQR, 3.4‒5.5) years of follow-up, 
78 KTR developed graft failure (13, 26, and 39 events across tertiles of 
cadmium; P<0.001). Plasma cadmium associated with increased risk 
of graft failure (HR 1.96, 95% CI 1.56‒2.47 per log2 ng/L; P<0.001). 
Similarly, a dose-response relationship was observed over increasing 
tertiles of plasma cadmium. Our fi ndings were independent of adjustment 
for potential confounders (e.g., donor, recipient, transplant and lifestyle 
characteristics), robust in competing risk analyses and in sensitivity 
analyses without outliers, and consistent over the secondary end-point 
kidney function decline (graft failure or doubling of serum creatinine). 
An apparent association of cadmium with all-cause mortality was lost 
in graft failure-censored analyses. In conclusion, plasma cadmium is 
independently associated with increased risk of long-term kidney graft 
failure and function decline. Further studies are warranted to confi rm 
our results and to investigate whether, in diff erent populations with 
regards to exposure, cadmium represents an ‒otherwise overlooked‒ 
modifi able risk factor for adverse long-term kidney graft end-points.




Kidney transplantation is the gold-standard treatment for most patients with end-stage kidney disease (ESKD). Notwithstanding that advances 
in transplant research have largely improved 1-year graft survival rates beyond 
90%, improvement of long-term graft survival continues to lag behind.1
Diagnosis and prevention of long-term kidney graft failure is subsidized by 
systematic identifi cation of both immune and non-immune mechanisms that 
‒over a background of donor and recipient risk factors‒ enclose potential 
hazards for adverse graft end-points.2
 There is increasing international awareness that heavy metals are 
meaningful chronic kidney disease (CKD) risk factors.3,4 Cadmium is 
a toxic heavy metal, of which primary sources of exposure in the general 
population are food and tobacco.5 Once absorbed, it is retained in the 
system in a long-lasting manner, with the kidney being the primary organ in 
which cadmium accumulates and causes toxicity. Reason is that after being 
bound to metallothionein and temporarily stored in the liver, the cadmium-
metallothionein-complex is released into the circulation, fi ltered by the 
glomerulus and subsequently reabsorbed by the proximal tubule epithelial 
cells, wherein cadmium accumulates with a half-life of up to 45 years.6–9
Cadmium-induced oxidative stress poses a major hazard for kidney integrity. 
Its exposure has been associated with glomerular and proximal tubular damage, 
proteinuria and organ dysfunction.7–17 Both occupational and environmental 
cadmium exposure have been shown to be associated with greater urinary 
excretion of kidney damage biomarkers, and with increased risk of ESKD and 
renal replacement treatment.7,14,18–23
 Better detection techniques allowing for quantifi cation of smaller 
amounts of heavy metals have made it possible to fi nd harmful eff ects on 
health below levels formerly considered as thresholds of toxicity, thereby 
increasing recognition of adverse consequences of chronic environmental 
–non-occupational– exposure to heavy metals. Cadmium, in particular, has 
been associated with increased risk of CKD even at low levels of exposure.14,23
Moreover, in settings of long-term, ongoing oxidative stress, cadmium-
induced nephrotoxicity has been associated with impaired kidney function, 
even at concentrations that are otherwise considered non-toxic.24–26 Kidney 
transplant recipients (KTR) are chronically exposed to oxidative stress due 
to maintenance immunosuppressive therapy, decreased kidney clearance, and 
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other, often co-occuring pro-oxidant conditions, such as aging, hypertension, 
and diabetes.27 We, therefore, hypothesized that cadmium exposure represents 
an overlooked hazard for preserved graft functioning. To date, however, 
there is a paucity of studies devoted to investigating whether cadmium may 
independently contribute to increased risk of adverse kidney graft end-points.
 In the Netherlands, environmental cadmium exposure rates are relatively 
low and other sources than food do not signifi cantly increase cadmium 
exposure,28 which makes the TransplantLines Food and Nutrition Biobank 
and Cohort Study29 ideal for epidemiologic studies evaluating whether 
cadmium –at even relatively low levels– associates with increased risk of 
adverse long-term kidney graft end-points. With a strong body of evidence 
suggesting that the hazardous exposure to cadmium may be susceptible to 
clinical monitoring and modifi able by non-toxic therapeutic interventions, 
assessment and characterization of cadmium-associated risk may provide 
rationale for development of novel risk-management strategies post-kidney 
transplantation.30 Although the majority of circulating cadmium is in red 
blood cells, the proximal tubule ‒which of the kidney is the most sensitive 
part to the toxic eff ects of cadmium‒ may not only be exposed to plasma 
containing cadmium via diff usion from red blood cells on its serosal side, but 
also on its luminal side where it is exposed to plasma ultrafi ltrate, which is 
known to contain the cadmium-metallothionein-complex.31 Because plasma 
is an intermediate in both potential pathways of exposure of the kidney, we 
set out to investigate the association of plasma cadmium concentrations with 
adverse kidney graft outcomes in this large cohort of KTR. We additionally 
aimed to identify subgroups of KTR at particularly high risk according to 
potential pathophysiology-based eff ect-modifi ers. In secondary analyses, we 
also investigated the association of plasma cadmium concentration with long-
term kidney function decline and patient survival end-points.
RESULTS
Baseline characteristics
We included 672 KTR (53±13 years-old, 58% male). Mean eGFR was 43±20 
mL/min/1.73 m2. Median (IQR) cadmium concentration was 58 (43‒75) ng/L. 
Using cut-off s of 500 and 1500 ng/L for hazardous and toxic concentrations, 
respectively, a single study subject was observed in each of such categories.32
Detailed description of baseline characteristics by tertiles of the study 
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population according to plasma cadmium distribution is shown in Table 1. 
Cadmium and risk of late graft failure
During a median follow-up of 4.9 (IQR, 3.4‒5.5) years, 78 KTR developed 
graft failure (12%), with a signifi cantly diff erent distribution across tertiles of 
plasma cadmium (13, 26, and 39 events, respectively; P<0.001; Figure 1A).
In crude analyses, cadmium concentration was associated with risk of graft 
failure (HR 1.89, 95% CI 1.47‒2.43 per log2 ng/L; P<0.001). Patients in either 
the middle or the highest tertile of cadmium were at higher risk of graft failure 
(HR 2.19, 95% CI 1.13‒4.27; and, HR 3.38, 95% CI 1.80‒6.33, respectively) 
compared to patients in the lowest tertile. In multivariable-adjusted analyses, 
these fi ndings remained materially unchanged (Table 2; Figure 2).33
Eff ect-modifi cation and stratifi ed analyses
Eff ect-modifi cation of the association between plasma cadmium and risk of 
graft failure are shown in Table S1. Aspartate aminotransferase and alanine 
aminotransferase were found signifi cant eff ect-modifi ers (Pinteraction 0.003 and 
0.005, respectively). In stratifi ed analyses (cut-off  point 25 U/L), we found that 
the association of plasma cadmium with risk of graft failure was signifi cant 
across both patients’ strata, however, KTR with levels of liver enzymes higher 
than 25 U/L were at particularly increased risk of graft failure (Figure 3). 
Description of extreme outliers
Description of extreme outliers is provided in Supplemental Results. 
Sensitivity analyses
We identifi ed 32 outliers (plasma cadmium >123 ng/L). In sensitivity analyses 
with exclusion of all and extreme outliers from the third tertile, plasma 
cadmium remained signifi cantly associated with risk of graft failure (HR 3.17, 
95% CI 1.66‒6.05; and 3.29, 95% CI 1.74‒6.20, respectively). This fi nding 
remained materially unchanged in further multivariable-adjusted analyses. 
Table 2 provides e-values for the observed coeffi  cient estimate and lower 
limit of the confi dence interval in death-censored and competing risk analyses 
of graft failure, per doubling of plasma cadmium and for patients in the third 
tertile after exclusion of extreme outliers. Finally, in 198 KTR with data about 
socioeconomic status (SES), cadmium associated with risk of graft failure 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1. Kaplan-Meier curve for (A) death-censored graft failure (nevents=78) 
and (B) kidney function decline (nevents=95), according to tertiles of plasma 
cadmium distribution. Tertile 1, ≤48 ng/L; tertile 2, 48‒68 ng/L; tertile 3, 
≥69 ng/L. P were calculated by log-rank test. Graft failure was defi ned as 
return to dialysis or re-transplantation. Kidney function decline was defi ned 
as doubling of serum creatinine or graft failure. 
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Cadmium and risk of kidney function decline, graft loss and mortality 
During a median follow-up of 4.9 (IQR, 3.4‒5.5) years, 95, 137, and 190 
patients developed kidney function decline, died, or were recorded for the 
composite end-point graft loss, respectively. Table S4 summarizes the 
number of events of all outcomes under study, overall the study population 
and by tertiles of plasma cadmium distribution. A Kaplan-Meier curve for the 
secondary end-point kidney function decline, according to tertiles of plasma 
cadmium distribution (22, 29, and 44 events, respectively; P=0.001) is shown 
in Figure 1B. Plasma cadmium was independently associated with kidney 
function decline in both continuous and categorical analyses, as well as after 
exclusion of outliers (Table 3). Plasma cadmium was also independently 
associated with graft loss (Table S5). The association with all-cause mortality 
was mainly driven by graft failure (Tables S6 and S7).
Serial  plasma cadmium levels in a sample population of the 
TransplantLines cohort and biobank study
In Figure S134we show box plots with medians (IQR) of plasma cadmium 
concentration of 46 KTR (mean age 52±14 years-old, eGFR 43±28 mL/
min/1.73 m2) from the TransplantLines Prospective Cohort and Biobank 
Study. Median (IQR) plasma cadmium concentrations were 78 (71─93), 70 
(60─100), 76 (67─98), 79 (63─89) ng/L, at 3-months, 6-months, 1-year, and 
2-years post-transplantation, respectively.
 Median (IQR) intra-individual coeffi  cient of variation post-transplantation 
was 2.9% (1.9─4.5), and we did not fi nd signs of a signifi cant change in 
plasma cadmium levels post-transplantation (P=0.89). In Figure S234we show 
that (A) plasma cadmium at 3-months post-transplantation was signifi cantly 
diff erent than plasma cadmium at admission for transplantation (median 
(IQR), 78 (71─93) and 100 (75─126) ng/L, respectively; P<0.001), and that 
(B) plasma cadmium at transplantation was signifi cantly associated (Std. 
β=0.71, P<0.001) with plasma cadmium at 3-months post-transplantation 
(R2=0.51). 
Blood versus plasma cadmium levels in participants of the TransplantLines 
cohort and biobank study
In Figure S3 we show the association of whole blood cadmium with 
plasma cadmium concentration (Std. β=0.52, P=0.001) in 116 KTR of the 
TransplantLines Prospective Cohort and Biobank Study.





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In Figure S4 we show the association of (A) plasma (Std. β=─0.19, 
P=0.046) and (B) whole blood (Std. β=0.07, P=0.47) cadmium concentrations 
with eGFR. Plasma but not blood cadmium was signifi cantly associated with 
estimated glomerular fi ltration rate. In further analyses with adjustment for 
hematocrit, the association between plasma cadmium and eGFR became 
stronger (Std. β=─0.24, P=0.01), and the association between whole blood 
cadmium and eGFR changed towards a non-signifi cant inverse association 
(Std. β=─0.02, P=0.81).
DISCUSSION
In a large  cohort of outpatient KTR, this study shows that plasma cadmium 
is independently and consistently associated with risk of long-term kidney 
graft failure and function decline. In line with previous literature in the fi eld, 
we observed a dose-dependent association between cadmium concentration 
and risk of adverse long-term kidney function end-points.7 These fi ndings 
are in agreement with previous evidence indicating that the kidney is the 
most sensitive target organ of cadmium-induced body burden,7,10–17 and with 
current international awareness of heavy metals as meaningful risk factors 
in CKD patients.3,4 Particularly in the outpatient kidney transplantat setting, 
this is the fi rst clinical study describing a prospective association of cadmium 
with adverse long-term end-points. The current study also provides clinical 
data to suggest that the hazardous association between plasma cadmium and 
long-term graft failure is particularly substantial in patients with relatively 
higher liver enzymes levels. Our results point towards cadmium exposure 
as a potentially modifi able ‒yet rather overlooked‒ risk factor for long-term 
graft failure in KTR, and may raise the question whether plasma cadmium 
monitoring and non-toxic therapeutic interventions to decrease bodily 
cadmium concentrations could represent novel risk management strategies to 
decrease the burden of long-term kidney graft failure. 
To our knowledge, the current is the fi rst study to investigate the association 
of plasma cadmium with clinical end-points. Most of previous studies on 
mammals have measured cadmium in urine or whole blood samples.15
Our fi ndings on that plasma cadmium, but not whole blood cadmium was 
signifi cantly and inversely associated with eGFR and that plasma cadmium 
was strongly associated with graft failure may provide rationale and further 
support our hypothesis that plasma rather than whole blood cadmium is 
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suitable for the study of cadmium-associated nephrotoxicity and adverse long-
term outcomes.
 Food and tobacco are the primary sources of cadmium exposure in the 
general population.5 After ingestion or inhalation, cadmium is temporarily 
stored in the liver bound to metallothionein.5,24 Pathophysiologically in 
agreement with the eff ect-modifi cation of liver enzymes on cadmium-
associated risk of graft failure hereby reported, cadmium-metallothionein is 
thereafter ‒upon hepatocytes turnover‒ released into the circulation, fi ltered 
at the glomerulus, and reabsorbed at the proximal tubule as a result of its 
preferential uptake by receptor-mediated endocytosis.25 With a kidney half-
life of up to 45 years, a build-up of cadmium in the proximal tubule will 
ensue.9 Herein, cadmium is degraded in endosomes and lysosomes, releasing 
free Cd2+ into the cytosol, where it generates reactive oxygen species (e.g., 
superoxide anion, hydrogen peroxide, and hydroxyl radicals) and activates 
redox sensitive transcription factors (e.g., NF-κB, AP-1 and Nrf2), which 
play a major role in cadmium-associated kidney pathophysiolology24 through 
activation of cell death pathways involving p53, thus linking long-term 
cadmium exposure with proximal tubular cell apoptosis (HK-2 cells)35 and 
impaired reabsorption of low molecular weight proteins. In line, it has been 
found that cadmium exposure is associated with increased urinary excretion 
of N-acetyl-β-D-glucosaminidase (NAG), retinol binding protein, and α1- 
and β2-microglobulin. It is thought that as tubular injury progresses, more 
generalized tubular dysfunction occurs.25 Prozialeck et al. recently showed 
that kidney injury molecule-1 (KIM-1) outperforms classic biomarkers of 
cadmium-induced nephrotoxicity.36 Further studies, and particularly human 
studies, have shown that urinary KIM-1 displays a better dose-response 
association with long-term low-dose cadmium exposure.37–40 Although in the 
current study we show that plasma cadmium strongly correlates with urinary 
excretion of two novel tubular damage biomarkers, i.e., epidermal growth 
factor and liver-type fatty acid-binding protein,41 future investigations in KTR 
are warranted to investigate the association of plasma cadmium with urinary 
excretion of other low-molecular weight proteins and KIM-1. Finally, although 
potential cadmium-associated glomerular injury has received relatively little 
attention, it should be underscored that there is a meaningful body of evidence 
linking cadmium exposure with glomerular damage and decreased glomerular 
fi ltration rate.7,14,19,22,23,42,43
 Because cadmium-induced hypertension has been previously reported, 
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it could be hypothesized that at least part of the cadmium-associated risk 
of graft failure is attributable to an intermediary role of augmented blood 
pressure.44–47 Although across tertiles of plasma cadmium distribution systolic 
blood pressure was not diff erent, we did observe a direct relation with use of 
antihypertensive medication. It should be noted, however, that in the present 
study the association between cadmium and graft failure was independent 
of systolic blood pressure, which supports that cadmium is linked to kidney 
tissue injury and dysfunction through proposed direct mechanisms at the 
kidney proximal tubule. 
 It should be realized that the current study is etiological in nature, which 
needs to be separated from prediction research.48 Whereas the latter is a distinct 
fi eld of epidemiologic research aimed at predicting the risk of an outcome 
according to a model of statistically signifi cant predictors, which not necessarily 
represent causal associations, etiological studies aim to understand a certain 
pathway of a disease in an attempt to prevent its onset or progression.48 This 
diff erentiation is relevant because in both scientifi c and clinical practice, the 
two kinds of analyses are often confused, reportedly resulting in poor-quality 
publications with limited interpretability and applicability. We remark on that, 
whereas its observational design does not allow causality assumptions, the 
current study is etiological in nature, and that taking together our fi ndings 
and those of previous studies showing a plausible biological link between 
cadmium exposure and kidney damage, it is possible to support an etiological 
role of cadmium in pathways of disease that contribute to increased risk of 
graft failure in KTR.
 Previous cohort studies performed in the general population have shown 
that cadmium is adversely associated with survival.49 We therefore additionally 
aimed to provide data on patients’ survival and the composite end-point 
graft loss to account for both graft and patients’ survival. When studying 
the broader end-point graft loss (defi ned as graft failure or death), increased 
cadmium-associated risk was consistent in analyses of patients in the highest 
tertile of plasma cadmium distribution, as well as in analyses of continuous 
increment of plasma cadmium. On the other hand, we observed that an 
apparent association of cadmium with all-cause mortality was mainly driven 
by graft failure, as shown in graft failure-censored analyses. These fi ndings 
remark on the epidemiological relevance of cadmium exposure, as accounted 
by the clinically relevant end-point graft loss, whereas they emphasize that 
cadmium-associated hazard acts mainly through its nephrotoxic eff ects to 
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increase the burden of adverse end-points in the long-term setting post-kidney 
transplantation. 
 Remarkably, our study was conducted in the northern part of The 
Netherlands, an area with known low environmental exposure rates to cadmium, 
both in soil and air.50 The life-long Dutch dietary intake of cadmium is below 
the European Food Safety Authority tolerable weekly cadmium intake of 2500 
ng/kg body weight.28 The largest Western-European cohort study on cadmium, 
the Cadmibel study conducted in Belgium, reported whole blood cadmium 
concentrations –within the normal range– to be associated with kidney tubular 
dysfunction.18 Mining and metal industry countries, e.g., China ‒which is the 
world’s leading country on cadmium production since 2014‒, have markedly 
increased patients’ cadmium exposure.51–53 Due to the dose-dependent eff ect 
suggested by the results of the current and previous studies, consequences of 
cadmium-associated kidney tissue injury may likely be more hazardous in 
such populations,7,18,28,50,51,53 yet we emphasize that heavy metals exposure-
associated CKD risk has been reported across all geographic regions.54
 Taken together, these fi ndings underscore that cadmium monitoring, 
reduction of environmental exposure, and non-toxic therapeutic interventions 
to decrease bodily cadmium concentrations, may be novel risk management 
strategies to decrease the current burden of long-term kidney graft failure. 
Because the kidney is thought to be the organ most critically vulnerable to 
cadmium accumulation, monitoring its specifi c organ built-up ‒by means, 
e.g., of an in vivo X-ray fl uorescence technique that using plane polarized 
X-rays allows a non-invasive assessment of kidney cortex cadmium‒ may be 
a particularly useful mean to assess the eff ects of accumulated cadmium on 
long-term kidney function end-points.55 Chelation therapy, used in heavy metal 
poisoning and iron overload syndrome, could henceforth off er an otherwise 
underestimated therapeutic approach. Lin et al. have repeatedly shown that the 
excretion of lead, a heavy metal with comparable nephrotoxicity to cadmium, 
can be increased by using Ca-EDTA (calcium ethylenediaminetetraacetic acid) 
chelation, which has been shown to slow progression rates of ESKD.56–62 Such 
results are promising for a potential cadmium-chelation therapeutic approach, 
particularly in KTR as being a population of high vulnerability to oxidative 
stress challenge and at high risk of kidney function impairment. Whether a 
novel cadmium-chelation pharmacological strategy may improve long-term 
graft survival rates warrants further studies. 
 We performed a prospective study in a large cohort of KTR, whom were 
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sequentially recruited during outpatient visits at our university hospital, and 
then closely monitored by regular check-up in the outpatient clinic during 
a substantial follow-up period; which granted comprehensive and updated 
end-points evaluation, without loss to follow-up. Additional strengths of the 
current study are that our fi ndings on the association of plasma cadmium 
with increased risk of graft failure were observed in a dose-response fashion 
in line with the literature, were robust in competing risk analyses as well 
as in sensitivity analyses with exclusion of outliers, and consistent over the 
secondary end-point kidney function decline (graft failure or doubling of 
serum creatinine). With baseline data being extensively collected, we were 
able to perform analyses with adjustment for several potential confounders. 
Whereas we acknowledge that we were not able to adjust our main analyses 
for SES in the whole study population, we provide the results of sensitivity 
analyses in a sample population of consecutively enrolled 198 KTR, to ponder 
towards the notion that the association of cadmium with risk of graft failure is 
independent of SES in Dutch KTR, which may also be in line with previous 
literature showing that SES does not infl uence the risk of CKD nor the risk 
of adverse long-term outcomes post-kidney transplantation in the egalitarian 
Dutch population.63,64 Next, although exposure was assessed using a single 
measure, we studied serial plasma cadmium levels in a sample population 
of the TransplantLines Cohort and Biobank Study,34 in which we found low 
intra-individual variability, indicative of relatively stable plasma cadmium 
levels over time post-transplantation. This fi nding additionally underscores 
that even at low levels, the nephrotoxic exposure to cadmium may represent 
an overlooked hazard for preserved graft functioning. We also acknowledge 
that our predominantly Caucasian study population was derived from a 
single center from the northern part of The Netherlands, which, as described 
before, calls for prudence to extrapolate these results to a diff erent population 
regarding potential environmental contamination and exposure to cadmium. 
 Our results, however, show for the fi rst time that plasma cadmium is 
independently associated with long-term risk of kidney graft failure, which 
was robust to several sensitivity analyses and consistent over additional graft 
function end-points, thus holding the plea for future studies to confi rm our 
results and externally validate our fi ndings among diff erent populations of 
KTR. We also call out for future studies to confi rm our fi ndings by comparing 
whole blood cadmium versus plasma cadmium concentrations for the study 
of cadmium-associated nephrotoxicity and adverse kidney outcomes. We 
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did not have data on urinary cadmium excretion, which might be a better 
marker of total body cadmium accumulation and therefore even stronger 
associated with eGFR and graft failure. Future studies will have to compare 
the prospective associations of plasma cadmium, whole blood cadmium 
and urinary cadmium with adverse kidney outcomes to sort this out. Next, 
we observed that cadmium associated with risk of graft failure in a dose-
response fashion, which has been consistently shown in previous literature 
and underscored to evidence causal cadmium-risk associations.12,65,66 While 
the prospective design of this study provides signals to formulate hypotheses 
regarding a causal link between cadmium and adverse kidney graft outcomes, 
we acknowledge that its observational nature prevents us from distinguishing 
whether plasma cadmium increases with decreasing eGFR or whether 
increased plasma cadmium levels cause a reduction in eGFR, and it does not 
allow for hard conclusions on causality. Neither could the potential presence 
of reversed causation, nor the possibility of residual confounding be entirely 
excluded. Despite the substantial number of potential confounders for which 
we adjusted, observational fi ndings on the association between cadmium and 
risk of graft failure are, by defi nition, prone to confounding, which is in line 
with the moderate to low e-values hereby reported.67 Finally, because we 
found that plasma cadmium concentrations at admission for transplantation 
were signifi cantly higher than at 3-months post-transplantation, and were 
also highly correlated with plasma cadmium at 3-months post-transplantation 
(in the sample population of KTR from the TransplantLines Prospective 
Cohort and Biobank Study), we hypothesize that cadmium exposure prior to 
transplantation may represent an otherwise overlooked contributing factor for 
increased risk of ESKD in the fi rst place. Our fi ndings warrant future studies 
to investigate a potential increased risk of ESKD associated with long-term 
cadmium exposure, even at relatively low levels as those of the KTR in this 
study, and to independently replicate our fi ndings in diff erent populations with 
regards to SES and environmental determinants of cadmium exposure. 
 In conclusion, the current study shows that in a Dutch cohort of outpatient 
KTR, higher plasma cadmium concentrations were independently associated 
with increased risk of long-term graft failure and kidney function decline. 
Cadmium exposure may be a potentially modifi able ‒yet rather overlooked‒ 
risk factor for adverse long-term kidney graft end-points. Our fi ndings on a 
particularly strong association between plasma cadmium and risk of kidney 
graft failure among patients with relatively higher liver enzymes levels, may 
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contribute with pathophysiological support to our fi ndings, and be clinically 
relevant to aid on generating individualized follow-up strategies of outpatient 
KTR. Further studies are needed to confi rm our results and to validate these 
fi ndings in diff erent populations with regards to exposure. Whether clinical 
monitoring of bodily cadmium concentrations, reduction of environmental 
exposure, and non-toxic therapeutic interventions to decrease system cadmium 
in outpatient KTR may represent novel risk management strategies to decrease 




Between November 2008 and March 2011, all adult KTR with a functioning 
allograft ≥1-year, visiting the outpatient clinic of the University Medical Center 
Groningen (The Netherlands) were invited to participate in the TransplantLines 
Food and Nutrition Biobank and Cohort Study, as described previously.29 A 
total of 707 of 817 (87%) eligible KTR signed informed consent. Pancreas 
transplant patients (n=1) and patients missing plasma cadmium measurements 
(n=34) were excluded from the current analyses, resulting in 672 KTR, of 
whom data is hereby presented (a fl owchart is shown in Figure S5). Additional 
information can be found in Supplemental Methods. The study protocol has 
been approved by the institutional review board (METc 2008/186) and was 
conducted in accordance with the Declaration of Helsinki and Istanbul.
Data collection and defi nitions
Medical and transplantation history as well as medication use were extracted 
from electronic patient records, including clinical history of past acute rejection. 
According to a strict protocol, all patients were asked to collect a 24 hours 
urine collection sample during the day before to their visit at the outpatient 
clinic. Blood was drawn in the morning after completion of the 24 hours urine 
collection. The measurement of clinical and laboratory parameters has been 
described in Supplemental Methods and in detail elsewhere.68 Blood and plasma 
cadmium concentrations were determined with use of an inductively coupled 
plasma mass spectrometer (ICP-MS, Varian 820-MS; Varian, Palo Alto, USA) 
with a validated method for the measurement of heavy metals in plasma 
as detailed in Supplemental Methods. Information on alcohol consumption 
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and smoking behavior was obtained by using a questionnaire.69 Diabetes 
was defi ned as the usage of antidiabetics or a fasting blood glucose ≥7.0 
mmol/L. Estimated glomerular fi ltration rate (eGFR) was calculated using the 
Chronic Kidney Disease Epidemiology Collaboration equation.70 In the fi rst 
n=198 consecutively enrolled KTR, SES was investigated using a self-report 
questionnaire at inclusion, categorizing education as described elsewhere71
according to the International Standard Classifi cation of Education: bachelor, 
master or doctorate graduate (level 1), postsecondary or non-tertiary or short-
cycle tertiary education (level 2), upper secondary education (level 3), lower 
secondary education (level 4), and primary or below primary education (level 
5). To investigate fi nancial status, participants were asked to choose among 
four possible categories: Short, enough, good, or excellent monthly budget. 
As described elsewhere,72 dietary intake was assessed using a 177 food items 
validated semi-quantitative food frequency questionnaire (FFQ) developed 
and updated at Wageningen University.69 Further information on the FFQ can 
be found in Supplemental Methods. 
Clinical end-points
The primary end-point of this study was graft failure, defi ned as the requirement 
of dialysis or re-transplantation. Secondary end-points were kidney function 
decline (defi ned as doubling of serum creatinine or graft failure), graft loss 
(defi ned as graft failure or death) and all-cause mortality. These endpoints 
were chosen to adhere to current recommendations and state of the art in the 
fi eld.73–76
For the analyses of graft failure, kidney function decline, and graft loss, 
patients who died with a functioning graft were censored at time of death. 
The study of all-cause mortality was performed with and without censoring 
at graft failure.
The surveillance system of the outpatient program at our university 
hospital ensures updated information on patient status and events of graft 
failure as assessed by a nephrologist. Within this system, patients visit the 
outpatient clinic with declining frequency, in accordance with the guidelines 
of the American Society of Transplantation.77 End-points were recorded 
until September, 2015. General practitioners or referring nephrologists were 




Serial measurements in participants the ongoing TransplantLines cohort 
and biobank study
Additionally, to investigate plasma cadmium levels over time, we requested 
follow-up plasma samples (at admission for transplantation, and at 3-months, 
6-months, 1-year, and 2-years post-kidney transplantation) from 46 KTR 
consecutively enrolled between February 2016 and May 2017 in the ongoing 
TransplantLines Prospective Cohort and Biobank Study.34 Cadmium plasma 
concentrations were determined using inductively coupled plasma mass 
spectrometry, as described in detail in Supplemental Methods. 
Blood versus plasma cadmium in participants of the ongoing 
TransplantLines cohort and biobank study
We also measured whole blood and plasma cadmium levels in 116 outpatient 
KTR at a median of 5.2 (IQR, 1.6─11.1) years post-transplantation ─which 
is comparable with transplant vintage of our prospective cohort study 
population─, to compare whole blood versus plasma cadium concentrations 
and to investigate the cross-sectional between cadmium concentration in each 
of these samples and eGFR. 
Statistical analyses
Data analyses were performed by using SPSS 23.0 for Windows (IBM, 
Chicago, Illinois, USA), GraphPad Prism 7.02 software (GraphPad Software 
Inc., San Diego, CA, USA), and R version 3.2.3 (R Foundation for Statistical 
Computing, Vienna, Austria). Baseline characteristics of study subjects were 
described by subgroup of patients according to tertiles of plasma cadmium 
distribution. Normally distributed variables are described as mean (SD), 
and skewed variables as median (IQR). Categorical variables are expressed 
as n (number) with percentage (%). Diff erences were studied with the chi-
squared test for categorical variables and by means of linear regression 
analyses for continuous variables. Variables with skewed distribution were 
natural log transformed, i.e., transplant vintage, cold ischemia time, aspartate 
aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma 
glutamyl transferase, low-density lipoprotein cholesterol, triglycerides, and 
blood glucose. A two-sided P<0.05 was considered signifi cant. 
 Analyses for testing diff erence and calculating intra-individual coeffi  cient of 
variation for follow-up plasma cadmium levels in KTR of the TransplantLines 
Cohort and Biobank Study can be found in Supplemental Methods. 




In prospective analyses of the primary end-point graft failure, a Kaplan-Meier 
curve and a log-rank test were performed to study whether the distribution of 
events was signifi cantly diff erent by subgroups of KTR according to tertiles 
of plasma cadmium concentration. The association of plasma cadmium 
concentration with risk of graft failure was further examined incorporating 
time to event by means of Cox proportional-hazards regression analyses 
(all assumptions were met as described in Supplemental Methods), in which 
plasma cadmium was log2-transformed to estimate regression coeffi  cients 
per doubling of plasma cadmium concentration. For these analyses, risk of 
death with a functioning graft was accounted by censoring at time of death 
and by performing competing risk analyses according to Fine and Gray.33 To 
illustrate the association of plasma cadmium (log2-transformed) with risk of 
graft failure, data were fi tted using median plasma cadmium concentration (58 
ng/L) as reference value. To study the eff ect of potential confounders, several 
Cox regression models were fi tted to the data. We performed adjustment for 
age and sex in model 1; and, eGFR, proteinuria, primary kidney disease, 
dialysis vintage, transplant vintage, acute rejection, cold ischemia time, 
human leukocyte antigens (HLA) mismatches, and donor type in model 2. 
Subsequently, we additively adjusted for body mass index, systolic blood 
pressure, glucose, and history of diabetes in model 3; and, lifestyle-related risk 
factors (i.e., smoking status and alcohol consumption) in model 4; induction 
therapy (anti-thymocyte globulin, IL2 receptor antibody, muromonab-CD3, 
and rituximab) in model 5; and dietary intake of diff erent food groups (e.g., 
cereals, potatoes, vegetables, fruits, legumes, nuts, meat, milk and dairy 
products, and fi sh and seafood) in model 6. 
 Potential eff ect-modifi cation by donor age, donor sex, donor type, recipient 
age, recipient sex, cold ischemia time, history of delayed graft function, 
eGFR, history of diabetes, systolic blood pressure, use of antihypertensive 
medication, aspartate aminotransferase, alanine aminotransferase, alkaline 
phosphatase, and gamma glutamyl transferase were tested by fi tting models 
containing both main eff ects and their cross-product terms. The Bonferroni-
adjusted signifi cance threshold (Pinteraction<0.006; calculated as described 
in Supplemental Methods) was considered to indicate the performance of 
stratifi ed prospective analyses. For these analyses, cut-off  points of originally 





We identifi ed plasma cadmium outliers by using Turkey’s fences (as described 
in Supplemental Methods),78 and analyzed Cox regression models analogous 
to the overall prospective analyses. Estimates are shown for patients pertaining 
to tertile 3 of plasma cadmium distribution in relation to patients pertaining 
to tertile 1 (reference group). Using the HR and CI calculated per doubling of 
plasma cadmium and for patients in tertile 3 of plasma cadmium distribution 
after exclusion of extreme outliers, we performed further sensitivity analyses 
as recommended for observational studies by means of providing e-values for 
both the observed association estimate and the limit of the CI closest to the 
null.67 We also performed sensitivity analyses in which we studied whether 
the association of cadmium with risk of late graft failure is independent of 
adjustment for SES.
Secondary analyses
In secondary analyses, we studied the association of plasma cadmium with 
the secondary end-points kidney function decline, graft loss, and all-cause 
mortality, by means of Cox regression models analogous to the study of the 
primary end-point graft failure.
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Excluded patients were comparable to the study population in terms of age, 
sex, BMI, waist circumference, smoking status, alcohol use, blood pressure, 
use of antihypertensive therapy, dietary intake, primary kidney disease, 
transplant history, eGFR and urinary protein excretion.
Cadmium analysis
Cadmium plasma concentrations were determined with use of an inductively 
coupled plasma mass spectrometer (ICP-MS, Varian 820-MS; Varian, Palo 
Alto, USA) with a modifi ed method for the measurement of low concentrations 
of heavy metals in plasma using a standard addition method. Standards were 
made by addition to blanc plasma known amounts of cadmium to obtain added 
concentrations of: 50; 100; 200; 300; 400 and 500 ng/L. Control samples were 
made by spiking blanc plasma with known amounts of cadmium to obtain 
added concentrations of respectively: 75 (low); 225 (medium) and 450 ng/L 
(high). Sample preparation consisted of diluting 100 µL sample with 1.0 mL 
dilution reagent. The dilution reagent contained 0.005% Triton X100, 0.005% 
EDTA and 0.1 mg/L Yttrium as internal standard. Characteristics of this 
method are summarized in Table S8.
Other laboratory measurements
Urinary epidermal growth factor was measured by ELISA (R&D Systems, 
Minneapolis, MN, USA). The test has a range of detection of 3.9–250 pg/
mL and the intra- and inter-plate coeffi  cients of variation were less than 10% 
and 15%, respectively.41 Urinary liver-type fatty-acid binding protein was 
measured with an enzyme-linked immunosorbent assay (human uL-FABP 
assay kit 96 test, CMIC holdings Co., Ld, Tokyo, Japan). The test has a range 
of detection of 0.3–60 ng/mL and the intra- and inter-plate coeffi  cients of 
variation were less than 5%.S1
Assessment of dietary intake
As described elsewhere,72 dietary intake was assessed using a validated semi-
quantitative food frequency questionnaire (FFQ) developed and updated at 
Wageningen University.69 The questionnaire consisted of 177 food items to 
record intake during the last month, taking seasonal variations into account. 
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For each item, the frequency was expressed in times per day, week, or month. 
The number of servings was recorded in natural units (e.g., slice of bread 
or apple) or household measures (e.g., cup or spoon). The FFQ was self-
administered and then checked by a trained researcher on the day of visit to 
the outpatient clinic. Inconsistent answers were verifi ed with the patients. The 
results of the FFQ were converted into total energy and nutrient intake per day 
by using the Dutch Food Composition Table of 2006.
Statistical analyses
The intra-individual coeffi  cient of variation (CV) for plasma cadmium levels 
in KTR of the TransplantLines Cohort and Biobank Study was calculated 
using the formula CV=(SD/mean) × 100, in which SD is the standard deviation 
and mean is the mean value for plasma cadmium concentrations as measured 
in follow-up samples taken at 3-months, 6-months, 1-year, and 2-years 
post-kidney transplant. Box plots were used to illustrate medians (IQR) of 
plasma cadmium levels at admission for transplantation and at post-transplant 
follow-up visits. Signifi cance of potential diff erence between cadmium at 
admission for transplantation and 3-months post-transplant was tested using 
the Wilcoxon matched-pairs signed rank test, and signifi cance of potential 
change during post-kidney transplant follow-up visits was tested using the 
Kruskal Wallis test.
Prospective analyses
We plotted Martingale residuals against age and kidney function to test which 
functional form of these covariates best fi tted the models. Schoenfeld residuals 
were calculated to assess whether proportionality assumptions were satisfi ed. 
We entered the quadratic and cubic terms of plasma cadmium with the linear 
term to assess the presence of nonlinear relationships (Table S9). A variance 
infl ation factor <5 indicates no evidence for collinearity.
Eff ect-modifi cation analyses
Potential eff ect-modifi cation by donor age, donor sex, donor type, recipient 
age, recipient sex, cold ischemia time, history of delayed graft function, 
eGFR, history of diabetes, systolic blood pressure, use of antihypertensive 
medication, aspartate aminotransferase, alanine aminotransferase, alkaline 
phosphatase, and gamma glutamyl transferase were tested by fi tting models 
containing both main eff ects and their cross-product terms. P<0.1 was 
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considered to indicate eff ect-modifi cation.S2 We then performed correction 
for multiple testing by means of the Bonferroni method. Because we have 
investigated potential eff ect-modifi cation for 15 variables, the corrected 
threshold based on the false discovery rate level of 0.1 was 0.1/15=0.006. 
This Bonferroni-adjusted signifi cance threshold (Pinteraction<0.006) was then 
considered to indicate the performance of stratifi ed prospective. For these 
analyses, cut-off  points of originally continuous variables were determined to 
concede clinically meaningful patients’ strata. 
SUPPLEMENTAL RESULTS
Description of extreme outliers
Out of all outliers, 11 participants (5% of patients pertaining to the highest tertile) 
were extreme outliers, with widely varying plasma cadmium concentrations 
(173‒3363 ng/L). The highest plasma cadmium concentration was more than 
5 times higher than the second highest plasma cadmium concentration. This 
particular patient, male, 37 years-old at the time of inclusion, was initially 
transplanted in 1995 because of polycystic kidney disease and had an eGFR 
of 32 mL/min/1.73 m2. He was a current smoker at time of inclusion, and 
had an extensive graft failure history: after a fi rst transplantation, the patient 
developed acute rejection, and a re-transplantation was eventually performed 
in 2003. Thereafter the patient returned to dialysis due to loss of glomerular 
function in 2010, and underwent a third renal transplantation in 2016. Among 
the other extreme outliers, 6 had diabetes at inclusion, 3 developed graft 
failure during follow-up and 2 deceased.
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Table S1. Eff ect-modifi cation analyses on the association of plasma cadmium 
with graft failure
Pre-defi ned potential eff ect-modifi ers
Cadmium per log2 (ng/L)
B Pinteraction
Donor age, years 0.01 0.18
Donor sex, male, n ‒0.14 0.60
Donor type, deceased, n ‒0.22 0.50
Recipient age, years 0.01 0.44
Recipient sex, male, n 0.23 0.54
Cold ischemia time, hrs 0.004 0.78
History of delayed graft function, n ‒0.42 0.54
eGFR, mL/min/1.73 m2 ‒0.01 0.66
Diabetes, n ‒0.31 0.44
Systolic blood pressure, mmHg ‒0.001 0.93
Use of antihypertensive medication, n ‒1.01 0.23
Aspartate aminotransferase, U/L 0.09 0.003*
Alanine aminotransferase, U/L 0.06 0.005*
Alkaline phosphatase, U/L 0.01 0.22
Gamma glutamyl transferase, U/L 0.004 0.05
Eff ect-modifi cation on death-censored graft failure by pre-defi ned potential eff ect-
modifi ers was tested by fi tting models containing both main eff ects and their cross 
product terms. P<0.1 was considered to indicate eff ect-modifi cation. We then 
performed correction for multiple testing by means of the Bonferroni method. Because 
we have investigated potential eff ect-modifi cation for 15 variables, the corrected 
threshold based on the false discovery rate level of 0.1 was 0.1/15=0.006. *Pinteraction
below the Bonferroni-adjusted threshold (0.006).
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Table S2. Socioeconomic status and plasma cadmium in 198 kidney transplant 
recipients
Socioeconomic status
Tertiles of plasma cadmium
Ptrend
Tertile 1 Tertile 2 Tertile 3
Educational status
Level 1, n (%) 6 (9) 5 (8) 1 (2) 0.04
Level 2, n (%) 13 (20) 11 (17) 6 (9)
Level 3, n (%) 16 (24) 20 (30) 18 (27)
Level 4, n (%) 28 (42) 23 (35) 33 (50)
Level 5, n (%) 3 (5) 7 (11) 8 (12)
Financial status
Paid work, n (%) 36 (55) 26 (39) 23 (35) 0.02
Work not paid, n (%) 30 (46) 40 (61) 41 (62)
Diff erences among tertiles of the plasma cadmium distribution (tertile 1, ≤52 ng/L; 
tertile 2, 53‒72 ng/L; tertile 3, ≥73 ng/L), were studied by means of the χ2 test. Data 
on fi nancial status was missing in 2 patients. Education levels were bachelor, master 
or doctorate graduate (level 1), postsecondary or non-tertiary or short-cycle tertiary 
education (level 2), upper secondary education (level 3), lower secondary education 
(level 4), and primary or below primary education (level 5), as previously described73
according to the International Standard Classifi cation of Education (ISCED; UNESCO 
Institute for Statistics: International Standard Classifi cation of Education, ISCED 
2011. Paris, France, UNESCO, 2011).
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Table S3. Association of cadmium with risk of graft failure in 198 kidney 
transplant recipients
Models
Cadmium per log2 (ng/L)
HR 95% CI P
Death-censored analyses
Crude 1.64 (0.91─2.94) 0.102
Model 1 1.89 (0.99─3.59) 0.053
Model 2 1.91 (1.00─3.66) 0.049
Competing risk analyses
Crude 1.63 (0.87─3.04) 0.128
Model 1 1.92 (1.03─3.57) 0.041
Model 2 1.93 (1.03─3.63) 0.043
Cox proportional-hazards regression analyses were performed to assess the 
association of plasma cadmium concentration with risk of graft failure (nevents=28), 
fi rstly by accounting for death (with a functioning graft) by censoring at time of death 
and secondly by performing competing risk analyses according to Fine and Gray.33
Multivariable model 1 was adjusted for age and sex. Multivariable model 2 was 
adjusted for age, sex, educational level and fi nancial status.
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Tertile 1 Tertile 2 Tertile 3
nevents nevents nevents nevents
Past events
History of acute rejection 177 53 64 60
Delayed graft function 50 8 14 28
Outcomes
Graft failure 78 13 26 39
Kidney function decline 95 22 29 44
Graft loss 190 33 66 91
Death 137 21 48 68
Tertile 1, ≤48 ng/L; tertile 2, 48‒68 ng/L; tertile 3, ≥69 ng/L. The primary end-point of 
this study was graft failure, defi ned as the requirement of dialysis or re-transplantation. 
Secondary end-points were kidney function decline (defi ned as doubling of serum 
creatinine or graft failure), graft loss (defi ned as graft failure or death) and all-cause 
mortality. These endpoints were chosen to adhere to current recommendations and 
state of the art in the fi eld.73–75 The surveillance system of the outpatient program 
at our university hospital ensures updated information on patient status and events 
of graft failure as assessed by a nephrologist. Within this system, patients visit the 
outpatient clinic with declining frequency, in accordance with the guidelines of the 
American Society of Transplantation.77 End-points were recorded until September, 
2015. General practitioners or referring nephrologists were contacted in case the 
status of a patient was unknown. No patients were lost to follow-up.


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table S8. Bias and precision of cadmium measurements
Cadmium 
concentration n ng/L Bias (%)
Inter-assay coef.
SD (ng/L) CV (%)
Low 31 75 ‒12.0 15 23
Medium 35 225 3.5 26 11
High 37 450 ‒1.5 50 11
CV, coeffi  cient of variation; SD, standard diff erentiation.
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Table S9. Association of plasma cadmium and risk of graft failure – verifi cation 
of linearity
Model HR (95% CI) P
Univariate A
Log2 cadmium 1.89 (1.47─2.43) <0.001
Univariate B
Log2 cadmium 1.88 (0.97─3.65) 0.06
Log2 cadmium2 1.00 (0.90─1.11) 0.98
Univariate C
Log2 cadmium 2.35 (1.32─4.17) 0.004
Log2 cadmium2 1.40 (0.90─2.17) 0.14
Log2 cadmium3 1.06 (0.98─1.13) 0.13
Model 1 A
Log2 cadmium 1.96 (1.56─2.47) <0.001
Model 1 B
Log2 cadmium 1.98 (1.11─3.53) 0.02
Log2 cadmium2 1.39 (0.88─2.19) 0.16
Model 1 C
Log2 cadmium 1.98 (1.11─3.53) 0.02
Log2 cadmium2 1.39 (0.88─2.19) 0.16
Log2 cadmium3 1.06 (0.99─1.14) 0.11
Model 2 A
Log2 cadmium 1.89 (1.31─2.74) 0.001
Model 2 B
Log2 cadmium 2.88 (1.51─5.50) 0.001
Log2 cadmium2 1.09 (0.96─1.23) 0.18
Model 2 C
Log2 cadmium 3.02 (1.55─5.89) 0.001
Log2 cadmium2 1.24 (0.68─2.27) 0.49
Log2 cadmium3 1.02 (0.93─1.13) 0.49
Model 3 A
Log2 cadmium 1.87 (1.28─2.74) 0.001
Model 3 B
Log2 cadmium 2.89 (1.51─5.56) 0.001
Log2 cadmium2 1.09 (0.97─1.23) 0.17
Model 3 C
Log2 cadmium 3.10 (1.59─6.03) 0.001
Log2 cadmium2 1.34 (0.73─2.45) 0.35
Part I
168
Table S9. (continued)  
Model HR (95% CI) P
Log2 cadmium3
Model 4 A
Log2 cadmium 1.97 (1.37─2.83) <0.001
Model 4 B
Log2 cadmium 2.69 (1.41─5.11) 0.003
Log2 cadmium2 1.07 (0.94─1.20) 0.30
Model 4 C
Log2 cadmium 2.80 (1.44─5.45) 0.002
Log2 cadmium2 1.21 (0.66─2.21) 0.54
Log2 cadmium3 1.02 (0.93─1.12) 0.68
Model 5 A
Log2 cadmium3 2.04 (1.56─2.68) <0.001
Model 5 B
Log2 cadmium 1.98 (0.95─4.10) 0.07
Log2 cadmium2 0.99 (0.88─1.12) 0.92
Model 5 C
Log2 cadmium 2.55 (1.28─5.07) 0.008
Log2 cadmium2 1.48 (0.91─2.40) 0.11
Log2 cadmium3 1.07 (0.99─1.15) 0.10
Model 1: Adjusted for age and sex. Model 2: Model 1 + adjustment for eGFR, 
proteinuria, primary kidney disease, dialysis vintage, transplant vintage, acute 
rejection, cold ischemia time, human leukocyte antigens mismatches, and donor 
type. Model 3: Model 2 + adjustment for body mass index, systolic blood pressure, 
blood glucose, and history of diabetes. Model 4: Model 3 + adjustment for smoking 
and alcohol use. Model 5: Adjusted for age, sex, and dietary intake of diff erent food 
groups (e.g., cereals, potatoes, vegetables, fruits, legumes, nuts, meat, milk and dairy 
products, and fi sh and seafood).

















































Figure S1. Plasma cadmium concentrations in 46 KTR of the TransplantLines 
Prospective Cohort and Biobank Study,34 at diff erent follow-up visits post-
transplantation. Box plots show medians (interquartile range). Signifi cance 
of potential change during follow-up visits was tested using the Kruskal-
Wallis test, which indicated no signifi cant change over time (P=0.89). Median 
(interquartile range) intra-individual coeffi  cient of variation of plasma 
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Figure S3. Association of whole blood cadmium with plasma cadmium 
concentration (Std. β=0.52, P=0.001) in 116 KTR of the TransplantLines 
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Figure S4. Association of (A) plasma and (B) whole blood cadmium 
concentrations with eGFR in 116 KTR of the TransplantLines Prospective 
Cohort and Biobank Study.34 Plasma cadmium (R2=0.03; Std. β=─0.19, 
P=0.046), but not whole blood cadmium (R2=0.004; Std. β=0.07, P=0.47) was 
signifi cantly associated with estimated glomerular fi ltration rate.
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